MedTrace Logo

Sugammadex and Neostigmine at Residual Neuromuscular Blockade

NCT01006720 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 99

Last updated 2012-12-13

No results posted yet for this study

Summary

This study is designed to compare recovery times after reversal of a residual neuromuscular block (TOF-ratio 0.2) with different doses of either neostigmine or sugammadex.

Conditions

  • Residual Neuromuscular Block (TOF-ratio of 0.2)

Interventions

DRUG

Sugammadex

Single intravenous injection of either: Sugammadex 0.25 mg/kg (Sgx 0.25) Sugammadex 0.5 mg/kg (Sgx 0.5) Sugammadex 0.75 mg/kg (Sgx 0.75) Sugammadex 1.0 mg/kg (Sgx 1.0) Sugammadex 1.25 mg/kg (Sgx 1.25)

DRUG

Neostigmine

Neostigmine 10 µg/kg (Neo 10) Neostigmine 25 µg/kg (Neo 25) Neostigmine 40 µg/kg (Neo 40) Neostigmine 55 µg/kg (Neo 55) Neostigmine 70 µg/kg (Neo 70)

DRUG

Saline

Saline 0.9% (Saline)

Sponsors & Collaborators

  • Technical University of Munich

    lead OTHER

Principal Investigators

  • Heidrun Fink, PD Dr., MD · Klinik für Anaesthesiologie, Klinikum rechts der Isar der Technischen Universität München, Ismaninger Str. 22, 81675 München

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-03-31
Primary Completion
2009-07-31
Completion
2009-12-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01006720 on ClinicalTrials.gov